INTRODUCTION {#s1}
============

Genomic medicine is a rapidly growing field in oncology. In the past decade, we have seen growth in the number of new genomic tests available, and genomic testing is now often used to match patients to approved or investigational agents. However, genomic testing is expensive and may not be covered by insurance providers; thus, it can pose a significant financial burden on cancer patients. Currently, the literature on the cost of genomic testing in patients with cancer is limited. Although there are a few studies on the cost-effectiveness of genomic testing panel for specific cancer and subpopulation \[[@R1], [@R2]\], the comparison of prices of detection between different cancer types is largely unknown. Herein, we evaluate the prevalence of genomic alterations, the likelihood of detecting mutations and copy number alterations (CNAs) in actionable genes, and the relevant prices for detecting these alterations in several cancer types. This study aims to help researchers and practitioners understand the costs of identifying theoretically actionable alterations in multiple tumor types.

RESULTS {#s2}
=======

Table [1](#T1){ref-type="table"} shows the prevalence of testable mutations that were theoretically or pharmaceutically actionable and the average price for identifying one patient with mutations in actionable genes by cancer type. Among 986 breast cancer patients in TCGA data, 586 (59%) had mutations in genes that were theoretically actionable and tested in the FoundationOne test. The frequency of mutations in theoretically actionable genes ranged from 25% in ovarian cancer to 93% in endometrial cancer. The price ranged from \$22,907 in ovarian cancer to \$6,254 in endometrial cancer. The prevalence of testable mutations in pharmaceutically actionable genes is relatively lower. The frequency of mutations in pharmaceutically actionable genes ranged from 10% in ovarian cancer to 72% in endometrial cancer, with corresponding price ranging from \$55,556 in ovarian cancer to \$8,035 in endometrial cancer.

###### Prevalence of Actionable Mutations by Cancer Type

  cancer type                    Total number of patients   Theoretically Actionable   Pharmaceutically Actionable                           
  ------------------------------ -------------------------- -------------------------- ----------------------------- ---------- ----- ------ ----------
  breast                         986                        586                        59.4                          \$9,759    388   39.4   \$14,740
  colon adenocarcinoma           154                        129                        83.8                          \$6,924    105   68.2   \$8,507
  lung adenocarcinoma            248                        205                        82.7                          \$7,017    163   65.7   \$8,824
  lung squamous cell carcinoma   178                        150                        84.3                          \$6,883    95    53.4   \$10,868
  ovarian                        316                        80                         25.3                          \$22,907   33    10.4   \$55,556
  glioblastoma multiforme        283                        225                        79.5                          \$7,295    129   45.6   \$12,725
  endometrial cancer             248                        230                        92.7                          \$6,254    179   72.2   \$8,035
  kidney clear cell carcinoma    491                        234                        47.7                          \$12,170   98    20.0   \$29,058
  head and neck cancer           306                        252                        82.4                          \$7,043    132   43.1   \$13,445

Table [2](#T2){ref-type="table"} shows the prevalence of testable CNAs that were theoretically or pharmaceutically actionable and the price for identifying at least one actionable CNA. Notably, the rate of CNAs in theoretically actionable genes varied significantly by disease, from 475 (83%) of 571 glioblastoma multiforme patients to 15 (3%) of 504 clear cell renal cell carcinoma patients. Similarly, the prevalence of mutations in pharmaceutically actionable genes also varied substantially from 55% in glioblastoma multiforme patients to 1% in kidney clear cell carcinoma. Table [3](#T3){ref-type="table"} shows the prevalence of testable mutations and CNAs combined. In this table, we considered any patient who had at least one testable mutation or CNA as one actionable case. The table shows a higher prevalence and lower price than the first two tables. The prevalence of theoretically actionable mutations or CNAs was above 80% for all cancer types we studied except clear cell renal cell carcinoma where the prevalence was 50%. Endometrial cancer patients had the highest prevalence of 98%. Accordingly, the price ranged from \$5,897 to \$11,572 to identify one patient with theoretically actionable alterations. The prevalence of mutations or CNAs pharmaceutically actionable showed a similar pattern.

###### Prevalence of Actionable Copy Number Alterations by Cancer Type

  cancer type                    Total number of patients   Theoretically Actionable   Pharmaceutically Actionable                            
  ------------------------------ -------------------------- -------------------------- ----------------------------- ----------- ----- ------ -----------
  Breast                         1033                       535                        51.8                          \$11,199    281   27.2   \$21,324
  colon adenocarcinoma           427                        144                        33.7                          \$17,200    66    15.5   \$37,516
  lung adenocarcinoma            493                        175                        35.5                          \$16,338    67    13.6   \$42,678
  lung squamous cell carcinoma   489                        326                        66.7                          \$8,700     228   46.6   \$12,438
  Ovarian                        569                        410                        72.1                          \$8,049     224   39.4   \$14,732
  glioblastoma multiforme        571                        475                        83.2                          \$6,972     316   55.3   \$10,481
  endometrial cancer             504                        132                        26.2                          \$22,146    54    10.7   \$54,155
  kidney clear cell carcinoma    504                        15                         3.0                           \$194,631   5     1.0    \$585,859
  head and neck cancer           388                        204                        52.6                          \$11,031    90    23.2   \$25,000

###### Prevalence of Either Actionable Mutations or Actionable CNAs by Cancer Type

  cancer type                    Total number of patients   Theoretically Actionable   Pharmaceutically Actionable                           
  ------------------------------ -------------------------- -------------------------- ----------------------------- ---------- ----- ------ ----------
  breast                         962                        791                        82.2                          \$7,054    568   59.0   \$9,824
  colon adenocarcinoma           152                        142                        93.4                          \$6,209    118   77.6   \$7,471
  lung adenocarcinoma            172                        161                        93.6                          \$6,197    132   76.7   \$7,558
  lung squamous cell carcinoma   178                        170                        95.5                          \$6,073    141   79.2   \$7,322
  ovarian                        311                        254                        81.7                          \$7,102    140   45.0   \$12,883
  glioblastoma multiforme        273                        266                        97.4                          \$5,952    211   77.3   \$7,504
  endometrial cancer             242                        238                        98.4                          \$5,897    188   77.7   \$7,466
  kidney clear cell carcinoma    415                        208                        50.1                          \$11,572   86    20.7   \$27,992
  head and neck cancer           302                        278                        92.1                          \$6,301    171   56.6   \$10,244

Cost/case indicates the average cost for identifying one patient that has testable and actionable gene(s) based on FoundationOne test list price.

DISCUSSION {#s3}
==========

In this study we found significant variations in the prevalence of actionable gene mutations and CNAs among different types of tumors. This finding is in line with previous studies using hot-spot mutation testing platforms \[[@R7], [@R8]\]. However, for all the cancer types that we considered, the majority of patients had theoretically actionable gene mutations or CNAs that can be detected in one commercially available genomic test panel. In this paper, we focused on the next generation sequencing gene panels and did not consider routine tumor molecular profiling that may involve multiple assessments, each of which targets a single gene or type of mutation (e.g. HER2, BRCA1, BRCA2 in breast cancer, and EGFR, HER2, KRAS, and ALK in lung cancer). Although the price of a single gene test may be lower, it is likely that when traditional methods are used for multiple assessments, a larger quantity of DNA is needed and it leads to longer turnaround time. Given the rapidly growing number of genes tested in genomic test panels, we expect that the proportion of patients with testable and actionable gene mutations or CNAs will continue to grow. The number of targeted therapies has been growing rapidly in recent years. The targeted therapies in use today may cost 10,000 to 25,000 dollars for each treatment given. The genomic testing results can steer physicians and patients towards the experimental treatments that may be effective and away from the treatments that are unlikely to be effective for that patient. Combining the growing number of genes tested in panels with the growing number of expensive targeted drug therapies and the trend of falling prices for genomic tests, genomic testing is poised to become more cost-effective when the entire course of treatment is taken into account.

This study has several limitations. First, the prevalence of gene mutations and CNAs was based on TCGA data, which may not reflect advanced/metastatic disease. Second, mutations may differ in their functional impact, and thus not all mutations in actionable genes are actionable. Third, not all theoretically actionable alterations are actionable in the context of the specific disease or genomic co-alterations. Fourth, KRAS was considered actionable in our analyses, which may inflate the prevalence of actionable genes. Fifth, we focused on mutations and CNAs only, without taking fusions into account; use of assays such as FoundationOne which provide not only mutation and CNA but also fusion information and common fusions, would increase the prevalence of actionable genomes. Finally it is important to recognize that the actual actionability for patients depends heavily on the trial availability \[[@R9]\]. Nevertheless, this is the first study that aims at understanding the costs of identifying actionable alterations using a genomic testing panel.

MATERIALS AND METHODS {#s4}
=====================

We downloaded the most recent data from The Cancer Genome Atlas (TCGA) via the TCGA Data Portal \[[@R3]\]. TCGA provides data on clinical information, genomic characterization, and high-level sequence analysis of tumor genomes. In this study, we examined both somatic mutations and CNAs for nine cancer types: breast cancer, colon adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, ovarian cancer, glioblastoma multiforme, endometrial cancer, clear cell renal cell carcinoma, and head and neck cancer. For each cancer type, we determined the prevalence of specific somatic mutations and CNAs using TCGA data. Of note the TCGA data included a sample of patients with somatic mutation information, a sample of patients with CNA information and another subsample of patients with both somatic mutation and CNA information. We were not able to identify copy-neutral loss of heterozygosity (LOH) since this type of data was not provided by TCGA analysis group. Notice that we used curated TCGA somatic SNV nutation data instead of pipeline-generated SNV in this study. We only used focal copy number alterations, which were generated by GISTIC analysis. For the prevalence of CNAs, we used conservative thresholds to define copy number amplification and deletion. More specifically, if the copy number was above 6, the patient was considered to have copy number amplification, and if the copy number was below 1, the patient was considered to have copy number deletion; otherwise, the patient was considered to have non-significant CNAs. Such cutoffs are in line with reporting thresholds for next generation sequencing gene panels such as FoundationOne testing, on which we focus in our price calculation.

After establishing the prevalence of mutations and CNAs for the different cancer types that we studied, we matched it with the list of mutations that are testable in FoundationOne to obtain the prevalence of "testable" mutations and CNAs. We chose FoundationOne because it is a commonly used commercial genomic testing panel and because it is the only genomic testing panel currently available on the market with clear information on price and the list of genes that are covered in the test panel \[[@R4]\]. Starting from this testable list, we established the prevalence of "actionable" mutations and CNAs so as to arrive at a list that was both testable and actionable. Here, we distinguished between amplification and deletion for CNAs. Genes were determined as theoretically actionable if a FDA-approved or clinically available investigational drug either directly or indirectly targets the gene, as previously described \[[@R5]\]. For each gene under consideration, public Web sites (NCI Drug Dictionary, NCI Thesaurus, Selleckchem, Medkoo, DGIdb, PubMed, and [ClinicalTrials.gov](http://ClinicalTrials.gov)) were consulted to identify drugs that target the encoded protein at clinically relevant IC50 values, as determined experimentally. PubMed was used to search for relevant literature that demonstrated either preclinical or clinical sensitivity of the drug to genetic alterations in the gene of interest. Drugs targeting proteins downstream of the gene of interest (indirect targets) were also identified in this manner with corroborating published literature indicating their sensitivity to genetic alterations in the gene of interest. Potentially actionable genes are listed in Table [4](#T4){ref-type="table"}. As the impact of genomic analysis on therapeutic decisions may differ depending on specific genes, we have also included a table (Table [5](#T5){ref-type="table"}) that shows the five most frequently observed mutations for each tumor type to allow researchers to best assess the prevalence of actionable genes.

###### Therapeutic implications of potentially actionable genes

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene                                       Potential therapeutic implications                                                                                   Actionability         
  ------------------------------------------ -------------------------------------------------------------------------------------------------------------------- --------------- ----- -----
  ABL1                                       Treatment with ABL or BCR-ABL inhibitors                                                                             Yes             Yes   No

  ABL2                                       Treatment with ABL inhibitors                                                                                        Yes             Yes   No

  AKT1                                       Treatment with AKT or mTOR inhibitors                                                                                Yes             Yes   No

  AKT2                                       Treatment with AKT or mTOR inhibitors                                                                                Yes             Yes   No

  AKT3                                       Treatment with AKT or mTOR inhibitors                                                                                Yes             Yes   No

  ALK                                        Treatment with ALK inhibitors                                                                                        Yes             Yes   No

  AR[\*](#tfn_002){ref-type="table-fn"}      Resistance to anti-hormone therapy                                                                                   Yes             Yes   No

  ARAF                                       Treatment with RAF inhibitor                                                                                         Yes             No    No

  ATM                                        Treatment with PARP inhibitors                                                                                       Yes             No    Yes

  ATR                                        Treatment with PARP inhibitors                                                                                       Yes             No    Yes

  AURKA                                      Treatment with AURKA inhibitors                                                                                      Yes             Yes   No

  AURKB                                      Treatment with AURKB inhibitors                                                                                      Yes             Yes   No

  BAP1                                       Treatment with HDAC inhibitors                                                                                       Yes             No    Yes

  BCL2                                       Treatment with BCL2 inhibitor and potential resistance to mTOR inhibitors\                                           Yes             Yes   No
                                             Resistance to BCL2 inhibitor                                                                                                               

  BRAF                                       Treatment with BRAF inhibitors                                                                                       Yes             Yes   No

  BRCA1                                      Treatment with PARP inhibitors                                                                                       Yes             No    Yes

  BRCA2                                      Treatment with PARP inhibitors                                                                                       Yes             No    Yes

  CCND1                                      Treatment with CDK 4/6 inhibitors                                                                                    Yes             Yes   No

  CCND2                                      Treatment with CDK 4/6 inhibitors                                                                                    Yes             Yes   No

  CCND3                                      Treatment with CDK 4/6 inhibitors                                                                                    Yes             Yes   No

  CCNE1                                      Treatment with CDK 2 Inhibitors                                                                                      Yes             Yes   No

  CDK4                                       Treatment with CDK 4/6 inhibitors                                                                                    Yes             Yes   No

  CDK6                                       Treatment with CDK 4/6 inhibitors                                                                                    Yes             Yes   No

  CDKN1B                                     Treatment with CDK 2 Inhibitors                                                                                      Yes             No    Yes

  CDKN2A                                     Treatment with CDK 4/6 inhibitors                                                                                    Yes             No    Yes

  CDKN2B                                     Treatment with CDK 4/6 inhibitors                                                                                    Yes             No    Yes

  CDKN2C                                     Treatment with CDK 4/6 inhibitors                                                                                    Yes             No    Yes

  CHEK2                                      Treatment with Chk2 inhibitor                                                                                        Yes             Yes   No

  CSF1R                                      Treatment with CSF1R monoclonal antibody and inhibitors                                                              Yes             Yes   No

  DDR2                                       Treatment with DDR2 inhibitor                                                                                        Yes             Yes   No

  DNMT3A                                     High risk" factor of myelodysplastic or myeloproliferative disorders required for trial enrollment.                  Yes             No    No

  DOT1L                                      Treatment with DOT1L inhibitor                                                                                       Yes             Yes   No

  EGFR                                       Treatment with EGFR inhibitors                                                                                       Yes             Yes   No

  EPHA3[\*](#tfn_002){ref-type="table-fn"}   Treatment with Dasatinib                                                                                             Yes             Yes   No

  ERBB2 (HER2)                               Treatment with HER2 inhibitors, monoclonal antibodies, and targeted vaccines                                         Yes             Yes   No

  ERBB3 (HER3)                               Treatment with HER3 inhibitors                                                                                       Yes             Yes   No

  ERBB4 (HER4)                               Treatment with HER4 inhibitors                                                                                       Yes             Yes   No

  ESR1                                       Anti-hormone resistance                                                                                              Yes             No    No

  FGF10                                      Trial enrollment                                                                                                     Yes             Yes   No

  FGF14                                                                                                                                                                                 

  FGF19                                                                                                                                                                                 

  FGF23                                                                                                                                                                                 

  FGF3                                                                                                                                                                                  

  FGF4                                                                                                                                                                                  

  FGF6                                                                                                                                                                                  

  FGFR1                                      Treatment with FGFR1 inhibitors                                                                                      Yes             Yes   No

  FGFR2                                      Treatment with FGFR2 inhibitors                                                                                      Yes             Yes   No

  FGFR3                                      Treatment with FGFR3 inhibitors                                                                                      Yes             Yes   No

  FGFR4                                      Treatment with FGFR4 inhibitors                                                                                      Yes             Yes   No

  FLT1                                       Treatment with FLT1 inhibitors                                                                                       Yes             Yes   No

  FLT4                                       Treatment with FLT4 inhibitors                                                                                       Yes             Yes   No

  GNA11                                      Treatment with PKC and MEK inhibitors                                                                                Yes             Yes   No

  GNAQ                                       Treatment with PKC and MEK inhibitors                                                                                Yes             Yes   No

  HGF                                        Treatment HGF monoclonal antibody                                                                                    Yes             Yes   No

  HRAS                                       Treatment with MEK Inhibitors                                                                                        Yes             Yes   No

  IGF1R                                      Treatment with IGF1R monoclonal antibodies or inhibitors                                                             Yes             Yes   No

  IGF2                                       Treatment with IGF1R monoclonal antibodies or inhibitors                                                             Yes             Yes   No

  JAK1                                       Treatment with JAK inhibitors                                                                                        Yes             Yes   No

  JAK2                                       Treatment with JAK inhibitors                                                                                        Yes             Yes   No

  JAK3                                       Treatment with JAK inhibitors                                                                                        Yes             Yes   No

  KDR                                        Treatment with KDR inhibitors                                                                                        Yes             Yes   No

  KIT                                        Treatment with KIT inhibitors                                                                                        Yes             Yes   No

  KRAS                                       Treatment with MEK Inhibitors                                                                                        Yes             Yes   No

  MAP2K1                                     Treatment with MEK Inhibitors                                                                                        Yes             Yes   No

  MAP2K2                                     Treatment with MEK Inhibitors                                                                                        Yes             Yes   No

  MAP2K4                                     Treatment with JNK1 inhibitor                                                                                        Yes             Yes   No

  MAP3K1                                     Treatment with JNK1 inhibitor                                                                                        Yes             Yes   No

  MDM2                                       Treatment with MDM2 inhibitor or Nutlins that inhibit MDM2-p53 interaction.                                          Yes             Yes   No

  MET                                        Treatment with MET inhibitors (Crizotinib, Cabozantinib)                                                             Yes             Yes   No

  MPL[\*](#tfn_002){ref-type="table-fn"}     Treatment with JAK2 inhibitors.                                                                                      Yes             No    No

  MTOR                                       Treatment with mTOR inhibitors                                                                                       Yes             Yes   No

  MYCN                                       Treatment with BET inhibitors                                                                                        Yes             Yes   No

  NF1                                        Treatment with PI3K pathway inhibitors (PI3K/AKT/MTOR), MAPK pathway inhibitors (RAF/MEK/ERK), or HSP90 inhibitors   Yes             No    Yes

  NF2                                        Treatment with PI3K pathway inhibitors (PI3K/AKT/MTOR), MAPK pathway inhibitors (RAF/MEK/ERK), or HSP90 inhibitors   Yes             No    Yes

  NOTCH1                                     Treatment with Gamma Secretase inhibitors (GSIs)                                                                     Yes             Yes   No

  NOTCH2                                     Treatment with GSIs\                                                                                                 Yes             Yes   No
                                             Resistance to GSIs                                                                                                                         

  NOTCH3                                     Treatment with GSIs                                                                                                  Yes             Yes   No

  NPM1                                       Correlate with positive response to all-trans retinoic acid therapy and chemotherapy in AML.                         Yes             No    No

  NRAS                                       Treatment with MEK inhibitors                                                                                        Yes             Yes   No

  NTRK1                                      Treatment with NTRK1 (TrkA) inhibitor                                                                                Yes             Yes   No

  NTRK2                                      Treatment with NTRK2 (TrkB) inhibitor                                                                                Yes             Yes   No

  NTRK3                                      Treatment with NTRK3 (TrkC) inhibitor                                                                                Yes             Yes   No

  PDGFRA                                     Treatment with PDGFRA inhibitors                                                                                     Yes             Yes   No

  PDGFRB                                     Treatment with PDGFRB inhibitors                                                                                     Yes             Yes   No

  PIK3CA                                     Treatment with PI3K, AKT, or mTOR inhibitors                                                                         Yes             Yes   No

  PIK3CB                                     Treatment with PIK3CB inhibitors                                                                                     Yes             Yes   No

  PIK3R1                                     Treatment with PI3K, AKT or mTOR inhibitors                                                                          Yes             No    No

  PIK3R2                                     Trial selecting for mutations                                                                                        Yes             No    No

  PTCH1                                      Treatment with SMO inhibitors                                                                                        Yes             No    Yes

  PTEN                                       Treatment with p110beta, AKT, or mTOR inhibitors                                                                     Yes             No    Yes

  PTPN11                                     Treatment with MEK Inhibitors                                                                                        Yes             Yes   No

  RAD50                                      Treatment with PARP inhibitors                                                                                       Yes             No    Yes

  RAF1                                       Potential resistance to RAF inhibitors\                                                                              Yes             Yes   Yes
                                             Treatment with MEK inhibitors\                                                                                                             
                                             Resistance to Dasatinib                                                                                                                    

  RET                                        Treatment with Ret inhibitors                                                                                        Yes             Yes   No

  SMO                                        Treatment with SMO inhibitors                                                                                        Yes             Yes   No

  SRC                                        Treatment with SRC inhibitors                                                                                        Yes             Yes   No

  STK11                                      Treatment with mTOR or AMPK inhibitors                                                                               Yes             No    Yes

  SYK                                        Treatment with Syk inhibitors                                                                                        Yes             Yes   No

  TOP2A[\*](#tfn_002){ref-type="table-fn"}   Treatment with topoisomerase 2A inhibitors                                                                           Yes             Yes   Yes

  TSC1                                       Treatment with mTOR inhibitors                                                                                       Yes             No    Yes

  TSC2                                       Treatment with mTOR inhibitors                                                                                       Yes             No    Yes
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note. Genes were determined as theoretically actionable if there is an FDA-approved or clinically available investigational drug that either directly or indirectly targets the gene as previously described.

Borderline classification as actionable.

###### Top five most common mutations by cancer type

  Cancer type                    Gene     Percentage
  ------------------------------ -------- ------------
  breast                         PIK3CA   32.05%
  MAP3K1                         7.10%    
  PTEN                           3.55%    
  MAP2K4                         3.25%    
  NF1                            2.74%    
  colon adenocarcinoma           KRAS     37.66%
  PIK3CA                         16.88%   
  ATM                            13.64%   
  BRAF                           12.99%   
  NRAS                           9.74%    
  Lung adenocarcinoma            KRAS     24.19%
  NF1                            11.29%   
  EGFR                           10.89%   
  KDR                            10.48%   
  HGF                            10.08%   
  Lung squamous cell carcinoma   PIK3CA   15.17%
  CDKN2A                         14.61%   
  NF1                            11.80%   
  NOTCH1                         7.87%    
  PTEN                           7.87%    
  Ovarian                        NF1      2.53%
  BRCA1                          2.22%    
  BRCA2                          2.22%    
  EGFR                           1.90%    
  KIT                            1.58%    
  Glioblastoma multiforme        PTEN     30.74%
  EGFR                           26.15%   
  PIK3R1                         11.31%   
  PIK3CA                         10.60%   
  NF1                            10.25%   
  Endometrial cancer             PTEN     64.92%
  PIK3CA                         53.23%   
  PIK3R1                         33.47%   
  KRAS                           21.37%   
  FGFR2                          12.50%   
  Kidney clear cell carcinoma    BAP1     8.55%
  MTOR                           5.09%    
  PTEN                           3.67%    
  ATM                            2.44%    
  PIK3CA                         2.44%    
  Head and neck cancer           CDKN2A   21.57%
  PIK3CA                         20.92%   
  NOTCH1                         19.28%   
  ATR                            5.88%    
  NOTCH2                         5.23%    

Further, we examined a smaller list of "pharmaceutically actionable" genes as this is important for the clinical implementation of biomarker-based therapy \[[@R5]\]. These included genes that have already been linked to FDA-approval of a drug (e.g. BRAF inhibitors), and gene variants known to affect drug effectiveness or toxicity, and that affect dosing guidelines and/or drug label information. This list is derived from genes that have well-known pharmacogenomics associations with drugs available on the market based on the Pharmacogenomics Knowledgebase \[[@R6]\]. We provided the list of pharmaceutically actionable genes with the corresponding drugs in the [Supplementary Table S1](#SD1){ref-type="supplementary-material"}.

Finally, we calculated the average price of identifying one patient with actionable alterations, using the list price of FoundationOne (\$5,800) divided by the proportion of patients with at least one actionable alteration. Of note, we focused on the price of detecting "actionable patients". If the patient had more than one mutation, he/she would still be counted as one. By doing this, we avoided the problem of overestimating the number of patients detected for actionable genes.
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